FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048111331> ?p ?o ?g. }

• W2048111331 abstract "Rates of cardiovascular disease are higher among HIV-infected patients as a result of the complex interplay between traditional risk factors, HIV-related inflammatory and immunologic changes, and effects of antiretroviral therapy (ART). This study prospectively evaluated changes in cardiovascular biomarkers in an underrepresented, racially diverse, HIV-1-infected population receiving abacavir/lamivudine as backbone therapy. This 96-week, open-label, randomized, multicenter study compared once-daily fosamprenavir/ritonavir 1400/100 mg and efavirenz 600 mg, both with ABC/3TC 600 mg/300 mg, in antiretroviral-naïve, HLA-B*5701-negative adults without major resistance mutations to study drugs. We evaluated changes from baseline to weeks 4, 12, 24, 48, and 96 in interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble vascular adhesion molecule-1 (sVCAM-1), d-dimer, plasminogen, and fibrinogen. Biomarker data were log-transformed before analysis, and changes from baseline were described using geometric mean ratios. This study enrolled 101 patients (51 receiving fosamprenavir/ritonavir; 50 receiving efavirenz): 32% female, 60% African American, and 38% Hispanic/Latino; 66% (67/101) completed 96 weeks on study. At week 96, levels of IL-6, sVCAM-1, d-dimer, fibrinogen, and plasminogen were lower than baseline in both treatment groups, and the decrease was statistically significant for sVCAM-1 (fosamprenavir/ritonavir and efavirenz), d-dimer (fosamprenavir/ritonavir and efavirenz), fibrinogen (efavirenz), and plasminogen (efavirenz). Values of hs-CRP varied over time in both groups, with a significant increase over baseline at Weeks 4 and 24 in the efavirenz group. At week 96, there was no difference between the groups in the percentage of patients with HIV-1 RNA <50 copies/mL (fosamprenavir/ritonavir 63%; efavirenz 66%) by ITT missing-equals-failure analysis. Treatment-related grade 2–4 adverse events were more common with efavirenz (32%) compared with fosamprenavir/ritonavir (20%), and median lipid concentrations increased in both groups over 96 weeks of treatment. In this study of underrepresented patients, treatment with abacavir/lamivudine combined with either fosamprenavir/ritonavir or efavirenz over 96 weeks, produced stable or declining biomarker levels except for hs-CRP, including significant and favorable decreases in thrombotic activity (reflected by d-dimer) and endothelial activation (reflected by sVCAM-1). Our study adds to the emerging data that some cardiovascular biomarkers are decreased with initiation of ART and control of HIV viremia. ClinicalTrials.gov identifier NCT00727597" @default.
• W2048111331 created "2016-06-24" @default.
• W2048111331 creator A5004056785 @default.
• W2048111331 creator A5014972896 @default.
• W2048111331 creator A5017860407 @default.
• W2048111331 creator A5021428464 @default.
• W2048111331 creator A5032628656 @default.
• W2048111331 creator A5042040728 @default.
• W2048111331 creator A5049711413 @default.
• W2048111331 creator A5056578595 @default.
• W2048111331 creator A5069581471 @default.
• W2048111331 creator A5076360870 @default.
• W2048111331 creator A5077415127 @default.
• W2048111331 creator A5083402039 @default.
• W2048111331 date "2013-06-07" @default.
• W2048111331 modified "2023-10-06" @default.
• W2048111331 title "Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results" @default.
• W2048111331 cites W128919346 @default.
• W2048111331 cites W138587671 @default.
• W2048111331 cites W1426208733 @default.
• W2048111331 cites W1606409921 @default.
• W2048111331 cites W1767400858 @default.
• W2048111331 cites W1979036222 @default.
• W2048111331 cites W1983420300 @default.
• W2048111331 cites W1983856334 @default.
• W2048111331 cites W1992604744 @default.
• W2048111331 cites W2015440060 @default.
• W2048111331 cites W2021521769 @default.
• W2048111331 cites W2025723457 @default.
• W2048111331 cites W2039691644 @default.
• W2048111331 cites W2046166857 @default.
• W2048111331 cites W2049501844 @default.
• W2048111331 cites W2059576950 @default.
• W2048111331 cites W2064045324 @default.
• W2048111331 cites W2086415911 @default.
• W2048111331 cites W2092806749 @default.
• W2048111331 cites W2097749319 @default.
• W2048111331 cites W2103702352 @default.
• W2048111331 cites W2117678059 @default.
• W2048111331 cites W2131385233 @default.
• W2048111331 cites W2148314152 @default.
• W2048111331 cites W2157533742 @default.
• W2048111331 cites W2158934554 @default.
• W2048111331 cites W2164969455 @default.
• W2048111331 cites W2165158952 @default.
• W2048111331 cites W2166409471 @default.
• W2048111331 cites W2167709851 @default.
• W2048111331 cites W2332910040 @default.
• W2048111331 doi "https://doi.org/10.1186/1471-2334-13-269" @default.
• W2048111331 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3685599" @default.
• W2048111331 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23741991" @default.
• W2048111331 hasPublicationYear "2013" @default.
• W2048111331 type Work @default.
• W2048111331 sameAs 2048111331 @default.
• W2048111331 citedByCount "14" @default.
• W2048111331 countsByYear W20481113312015 @default.
• W2048111331 countsByYear W20481113312016 @default.
• W2048111331 countsByYear W20481113312017 @default.
• W2048111331 countsByYear W20481113312018 @default.
• W2048111331 countsByYear W20481113312019 @default.
• W2048111331 countsByYear W20481113312020 @default.
• W2048111331 countsByYear W20481113312022 @default.
• W2048111331 crossrefType "journal-article" @default.
• W2048111331 hasAuthorship W2048111331A5004056785 @default.
• W2048111331 hasAuthorship W2048111331A5014972896 @default.
• W2048111331 hasAuthorship W2048111331A5017860407 @default.
• W2048111331 hasAuthorship W2048111331A5021428464 @default.
• W2048111331 hasAuthorship W2048111331A5032628656 @default.
• W2048111331 hasAuthorship W2048111331A5042040728 @default.
• W2048111331 hasAuthorship W2048111331A5049711413 @default.
• W2048111331 hasAuthorship W2048111331A5056578595 @default.
• W2048111331 hasAuthorship W2048111331A5069581471 @default.
• W2048111331 hasAuthorship W2048111331A5076360870 @default.
• W2048111331 hasAuthorship W2048111331A5077415127 @default.
• W2048111331 hasAuthorship W2048111331A5083402039 @default.
• W2048111331 hasBestOaLocation W20481113311 @default.
• W2048111331 hasConcept C126322002 @default.
• W2048111331 hasConcept C142462285 @default.
• W2048111331 hasConcept C203014093 @default.
• W2048111331 hasConcept C2522874641 @default.
• W2048111331 hasConcept C2777869810 @default.
• W2048111331 hasConcept C2779298103 @default.
• W2048111331 hasConcept C2779465607 @default.
• W2048111331 hasConcept C2779778239 @default.
• W2048111331 hasConcept C2780593183 @default.
• W2048111331 hasConcept C2781432083 @default.
• W2048111331 hasConcept C2993143319 @default.
• W2048111331 hasConcept C3013748606 @default.
• W2048111331 hasConcept C71924100 @default.
• W2048111331 hasConcept C90924648 @default.
• W2048111331 hasConcept C98274493 @default.
• W2048111331 hasConceptScore W2048111331C126322002 @default.
• W2048111331 hasConceptScore W2048111331C142462285 @default.
• W2048111331 hasConceptScore W2048111331C203014093 @default.
• W2048111331 hasConceptScore W2048111331C2522874641 @default.
• W2048111331 hasConceptScore W2048111331C2777869810 @default.
• W2048111331 hasConceptScore W2048111331C2779298103 @default.
• W2048111331 hasConceptScore W2048111331C2779465607 @default.
• W2048111331 hasConceptScore W2048111331C2779778239 @default.
• W2048111331 hasConceptScore W2048111331C2780593183 @default.

• next